Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. (3rd April 2022)

• Record Type: Journal Article
• Authors: Thomas, Xavier; Elhamri, Mohamed; Deloire, Alexandre; Heiblig, Maël
• Is Part Of: Expert opinion on emerging drugs. Volume 27:Number 2(2022)
• Page Start: 169
• Page End: 185
• Publication Date: 2022-04-03
• Subjects: Acute myeloid leukemia -- monoclonal antibodies -- drug conjugate antibodies -- unconjugated antibodies -- bi-specific recombinant antibodies -- radio-conjugated antibodies -- CAR-T cells -- immune checkpoint treatments; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2022.2094365
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction: Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk profile, and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. Areas covered: The current paper reviews the clinical development of monoclonal antibody-based therapies in AML, their current status and phases 2 and 3 prospective trials. Expert opinion: Monoclonal antibody-based therapies demonstrated efficacy and tolerability in several clinical trials, especially when used in combination either with '3 + 7' chemotherapy or with low-intensity treatments. Additional studies are needed to determine new antigens for antibody-based therapies that target leukemia stem cells and spare normal hematopoiesis. Phase 2 and 3 additional clinical trial data are needed to assess the promise of first trials, especially regarding chimeric antigen receptor T cells redirected against myeloid antigens and immune checkpoint inhibitor therapies.